All In Biotech

Drug Trial Radar · NCT02500680

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)

A Phase IA/IB Trial to Evaluate the Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) With Hemagglutinin Dose Escalation Compared to Non-Adjuvanted Comparator Inactivated Influenza Vaccine (IIV) Standard Dose (SD) in Healthy Adults and High Dose (HD) IIV in Ambulatory Elderly Subjects

Last checked: Nov 19, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

102

Actual

Start

Jul 2015

Primary completion

Dec 2020

Study completion Dec 2020

Sponsor

Sponsor type
Industry
Collaborators
Mercia Pharma Inc.; Nova Laboratories Limited; The Emmes Company, LLC
First posted
Jul 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerance, and immunogenicity of MAS-1-Adjuvanted seasonal inactivated influenza vaccine (IIV) (MER4101) with hemagglutinin dose escalation compared to non-adjuvanted comparator IIV standard dose (SD) in healthy adults and high dose (HD) IIV in ambulatory elderly subjects. Hypothesis: Reduced HA dose IIV formulated in MAS-1 adjuvant (MER4101) has been shown under Phase 1A to be safe, tolerable and demonstrated a more robust and durable immune response to IIV over 6 months post-vaccination in healthy young adults 18 - 49 years of age compared to SD IIV. Under phase 1B, the 9 µg/HA dose of IIV in 0.3 mL MAS-1 was safe and well tolerated and immunogenically comparable to or better than 60 µg/HA HD IIV control over 3 to 6 months post-vaccination than HD IIV control. It is anticipated that the increased total dose of 15 µg HA antigen administered concurrently to opposite arms in 2 doses of 7.5 µg/HA IIV in 0.25 mL MAS-1 adjuvant emulsion will be safe, well tolerated, and more immunogenic than 9 µg/HA IIV in MAS-1, and will be more immunogenic when compared to HD IIV control in adults who are 65 years of age and older with the potential to provide better protection throughout the influenza season.

Conditions

  • Influenza, Human

Interventions

  • MER4101Biological

  • Inactivated Influenza VaccineBiological

    Fluzone quadrivalent Influenza Vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with solicited local and systemic AEsTime frame: 14 Days after Vaccination
  2. Number of Participants with Late-Onset Local and Systemic AEsTime frame: 16 days after Vaccination for the remaining duration of the study
  3. Number of Participants with laboratory abnormalitiesTime frame: 7, 14 and 28 Days after Vaccination
  4. Occurrence of vaccine-related SAEsTime frame: Duration of Study
  5. Geometric mean titer (GMT) of hemagglutination inhibition assay (HAI) antibodiesTime frame: 28 days after Vaccination
  6. Seroconversion rate of HAI antibody titerTime frame: 28 days after Vaccination
  7. Geometric mean fold increase (GMFI) of HAI antibodies (post-vaccination titer relative to pre-vaccination titer)Time frame: 28, 84, and 168 days after Vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Saint Louis University School of Medicine

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.